HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
88.42(c) 89.34(c) 90.35(c) 87.38(c) 88.03(c) Last
1 613 859 1 791 094 1 848 750 1 811 573 1 790 759 Volume
-4.82% +1.04% +1.13% -3.29% +0.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3 965 M - -
Net income 2022 940 M - -
Net cash position 2022 585 M - -
P/E ratio 2022 23,5x
Yield 2022 -
Sales 2023 4 565 M - -
Net income 2023 1 468 M - -
Net cash position 2023 2 272 M - -
P/E ratio 2023 16,0x
Yield 2023 -
Capitalization 20 237 M 20 237 M -
EV / Sales 2022 4,96x
EV / Sales 2023 3,94x
Nbr of Employees 1 940
Free-Float 98,1%
More Financials
Company
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and... 
Sector
Pharmaceuticals
Calendar
08/10Earnings Release
More about the company
Ratings of Horizon Therapeutics Public Limited Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
05/24Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint..
BU
05/23SVB Securities Initiates Horizon Therapeutics at Market Perform With $95 Price Target
MT
05/17Horizon Therapeutics Says First Patient Enrolled in Phase 2 Study of Proposed Treatment..
MT
05/17Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating D..
BU
05/17Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating D..
CI
05/16Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientV..
BU
05/13INSIDER SELL : Horizon Therapeutics
MT
05/11Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen's Associatio..
BU
05/11Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with ..
BU
05/09Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
BU
05/04Horizon Therapeutics Posts Higher Q1 Non-GAAP Earnings, Net Sales
MT
05/04TRANSCRIPT : Horizon Therapeutics Public Limited Company, Q1 2022 Earnings Call, May 04, 2..
CI
05/04HORIZON THERAPEUTICS PUBLIC LTD CO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL C..
AQ
05/04HORIZON THERAPEUTICS PUBLIC LTD CO : Results of Operations and Financial Condition, Change..
AQ
05/04HORIZON THERAPEUTICS : Q1 Earnings Snapshot
AQ
More news
News in other languages on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
05/17Horizon Therapeutics déclare que le premier patient s'est inscrit à l'étude de phase 2 ..
05/17Horizon Therapeutics plc annonce le recrutement du premier patient dans l'essai de phas..
05/04Horizon Therapeutics affiche une hausse de ses bénéfices non GAAP et de ses ventes nett..
05/04Earnings Flash (HZNP) HORIZON THERAPEUTICS affiche un chiffre d'affaires de 885,2 milli..
05/04Horizon Therapeutics Public Limited Company annonce ses résultats pour le premier trime..
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 88,03 $
Average target price 138,62 $
Spread / Average Target 57,5%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Aaron L. Cox Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Michael A. DesJardin Executive VP-Technical Operations & Quality
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-18.31%20 237
JOHNSON & JOHNSON6.04%472 179
PFIZER, INC.-9.55%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY10.77%272 388
ABBVIE INC.10.13%261 585